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Background: Drug-induced liver injury (DILI) refers to acute or chronic liver injury that may occur as a consequence of
using drugs and herbal or dietary supplements. Specific therapies for DILI are limited. There is considerable evidence
for efficacy and safety of N-acetylcysteine (NAC) in management of paracetamol-induced liver injury. More recently,
research has explored the use of NAC in non-paracetamol drug-induced liver injury. It is important to summarise the
evidence of NAC for non-paracetamol DILI to determine if NAC may be considered a therapeutic option in this condition.
Methods/design: We will conduct a systematic review of the benefit and harm of NAC in non-paracetamol drug-
induced liver injury. Primary and secondary outcomes of interest are pre-specified. Primary outcomes include all-cause
mortality, mortality due to DILI, time to normalisation of liver biochemistry (e.g. return of alanine transaminase to <100
U/l and/or international normalized ratio (INR) <1.5) and adverse events. Secondary outcomes include transplantation
rate, time to transplantation, transplant-free survival and duration of hospitalisation. We will include randomized
controlled trials (RCTs) and prospective cohort studies. RCTs will contribute to the evaluation of safety and efficacy of
NAC, whereas, the cohort studies will contribute exclusively to the evaluation of safety. We will search several
bibliographic databases (including PubMed, Scopus, CINAHL, CENTRAL), grey literature sources, conference proceedings
and ongoing trials. Following data extraction and assessment of the risk of bias, we will conduct a meta-analysis if
feasible, as well as subgroup analyses. We will assess and explore clinical and statistical heterogeneity.
Discussion: The aim of this review is to provide evidence on the effectiveness and safety of NAC in non-paracetamol
DILI. We anticipate that the results could aid health care practitioners, researchers and policymakers in the decision-
making regarding the use of NAC in patients with non-paracetamol DILI.
Systematic review registration: PROSPERO CRD42014008771
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Non-acetaminophenBackground
Drug-induced liver injury (DILI) refers to acute or chronic
liver injury that may occur as a consequence of using
drugs and herbal or dietary supplements [1, 2]. According
to recent estimates, the yearly incidence of DILI is esti-
mated to be between 14–19 cases per 100,000 [3, 4].* Correspondence: CHGMOH001@myuct.ac.za
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there is still a considerable potential for harm. In the USA,
it is the most common cause of acute liver failure, with
11 % of cases due to idiosyncratic DILI [5]. Moreover, the
true incidence of DILI may be underestimated due to
diagnostic difficulty as well as underreporting [2].
A number of risk factors are thought to be associated
with the development of DILI. In general, older age is a
risk factor, with DILI occurring more commonly in
adults compared with children [6]. While there seems to
be a biological basis for age as a risk factor, it may alsos article distributed under the terms of the Creative Commons Attribution
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tial hepatotoxins compared with children. However, age
as a risk factor does not always hold true, such that for
certain drugs, the risk is greater in children e.g. DILI
caused by valproic acid is more common in children. Fe-
males appear to be at a greater risk compared to their
male counterparts [7]. Certain genetic variations place
individuals at risk of DILI due to specific drugs e.g. isonia-
zid DILI and N-acetyltransferase 2 gene polymorphism as
well as the HLA-*B5701 genotype and flucloxacillin [8].
While these genetic variations have been shown to in-
crease the risk for the development of DILI, they do not
predict severity of injury. Pre-existing liver disease is a fur-
ther independent risk factor, with this being observed in
patients coinfected with viral hepatitis and tuberculosis
who develop DILI in response to antiviral and antituber-
culous drugs [9, 10]. Furthermore, alcohol abuse and
malnutrition are also risk factors associated with the de-
velopment of DILI [2].
The general management of DILI consists of the dis-
continuation of the offending drug in combination with
supportive treatment [2]. Patients often require pro-
longed hospital stays which may be costly to both pa-
tient and health service. Therapeutic re-challenge with
the offending drug is generally not recommended but
may be attempted in certain instances after a thorough
consideration of the risks and potential benefits. There
are specific therapies available for DILI caused by certain
drugs. However, these are limited to carnitine for val-
proic acid and N-acetylcysteine (NAC) for paracetamol
overdose [11, 12]. This limited availability highlights the
need for further research into therapies for DILI.
NAC was first used as a treatment for paracetamol
overdose in 1979 [13]. Since then, it has been firmly
established as an effective and safe treatment for this
condition [12]. NAC has also been shown to be safe and
effective outside of paracetamol overdose. NAC has been
evaluated as a treatment option for non-paracetamol
acute liver failure in adults and paediatric patients. In a
randomised clinical trial comparing NAC with placebo
in adults with non-paracetamol acute liver failure, NAC
was associated with an improvement in transplant-free
survival in a subgroup of patients with grade 1 and
grade 2 encephalopathy [14]. In a prospective study
conducted in adults with non-paracetamol acute liver
failure at a centre without the facility for transplantation,
the use of NAC was associated with a mortality benefit
[15]. In a retrospective study in paediatric patients with
non-paracetamol acute liver failure, NAC was associated
with a shorter hospital stay and improved survival post-
transplantation [16]. Furthermore, in a case series of
patients with DILI secondary to Amanita phalloides mush-
room poisoning, 10 out of 11 patients recovered fully after
receiving NAC in combination with other therapies [17].NAC has also been evaluated for non-liver related
clinical indications. These indications include its use as a
mucolytic agent in pulmonary diseases, in the preven-
tion of radio-contrast associated nephrotoxicity and for
the treatment of certain ophthalmic conditions [18–21].
In paracetamol overdose, a form of non-idiosyncratic
DILI, the pathogenesis underlying hepatotoxicity is fairly
well understood. Here, the metabolism of paracetamol
produces an excess of the hepatotoxic metabolite N-acetyl-
p-benzo-quinone imine (NAPQI). NAPQI is normally
inactivated by hepatic glutathione; however, glutathione is
depleted in paracetamol overdose. This results in an accu-
mulation of NAPQI with consequent hepatic cell injury
and death. NAC is thought to replenish hepatic glutathi-
one stores, which forms the basis for its efficacy in this
condition [22]. In contrast, the mechanism underlying
hepatotoxicity in idiosyncratic DILI does not involve
glutathione depletion. However, the precise pathogenesis
in idiosyncratic DILI is not clearly defined [23]. The pro-
posed pathogenic mechanisms in idiosyncratic DILI in-
clude direct cell injury, immune mediated damage and
mitochondrial injury. These mechanisms, especially those
that lead to mitochondrial damage, have significant impli-
cations. Mitochondria are involved in protecting hepato-
cytes against oxidative stress from oxygen-free radicals in
the liver. The damage and loss of mitochondria leads to
an accumulation of oxygen-free radicals and subsequent
oxidative cell damage. NAC may be of benefit in this con-
text through its antioxidant effect [24, 25]. Furthermore,
additional benefits of NAC in this context involve the im-
provement of systemic haemodynamics and tissue oxygen
delivery, as well as other favourable effects on the injured
liver [26, 27].
The aim of this systematic review is to review the evi-
dence of safety and effectiveness including improvement
in time, if any, to normalisation of liver function tests
and of NAC in non-paracetamol drug-induced liver in-
jury. NAC has already been established as a safe and ef-
fective treatment for paracetamol-induced liver injury.
Recently, the research focus has shifted to investigating
the use of NAC in non-paracetamol drug-induced liver
injury. It is important to review the evidence of NAC
safety and efficacy in this setting to determine if NAC may
be considered as a treatment option in non-paracetamol
drug-induced liver injury. The evidence from this research
may then be used to inform the decisions made by policy-
makers, health care practitioners, as well as researchers in
this area.Methods/design
This review protocol is registered in the PROSPERO
International Prospective Register of systematic reviews,
registration number CRD42014008771.
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Types of studies
We will include randomized controlled trials (RCTs) and
prospective cohort studies. RCTs will contribute to the
evaluation of safety and efficacy of NAC, whereas, the
cohort studies will contribute exclusively to the evalu-
ation of safety.
Language and timing
No language and time restrictions will apply.
Types of participants
Human participants of any age diagnosed with non-
paracetamol drug-induced liver injury and diagnosed ac-
cording to recognised diagnostic criteria [28–31].
Types of interventions
Intervention, N-acetylcysteine administered intravenously
or orally.
Control, placebo or standard of care (as described in
the study) or alternative therapy.
There will be no restriction on dose, timing and route
of administration of NAC.
Types of outcome measures
Results must include quantitative data for outcomes
measured.
Primary outcomes All-cause mortality, mortality due to
DILI, time to normalisation of liver biochemistry (e.g. re-
turn of alanine transaminase to <100 U/l and/or inter-
national normalized ratio (INR) <1.5), adverse events
(graded using the Common Terminology Criteria for
Adverse Events) [32].
Secondary outcomes Transplantation rate, time to
transplantation, transplant-free survival, duration of
hospitalisation.
Search methods for identification of studies
We will perform a comprehensive search of databases
and conference proceedings to identify all relevant stud-
ies available by October 2014, regardless of language or
publication status. We will search both peer-reviewed
journal articles and grey literature (unpublished, internal
or non-reviewed papers and reports).
Electronic searches
We will search the following electronic databases:
Cochrane Library, Medline via PubMed, SCOPUS, Web
of Science (SciELO), and EBSCO (CINAHL, Africa-
Wide, Academic Search Premier). We will use both text
words and medical subject heading (MeSH) terms. The
literature search strategy will be adapted to suit eachdatabase. Briefly, we will use a combination of the follow-
ing terms: N-acetylcysteine, Acetylcysteine, Drug-induced,
Hepatitis, Liver, Liver Failure, Non-paracetamol, Non-
acetaminophen.
The detailed search strategy is provided in Additional
file 1.
Conference proceedings
We will conduct a manual search of relevant abstracts
or proceedings of the following conferences (2000 to
present): American Association for the Study of Liver
Diseases (AASLD) Drug-Induced Liver Injury Confer-
ence, AASLD-FDA-NIH-PhRMA-Hepatotoxicity Special
Interest Group Conferences, European Association for
the Study of Liver (EASL), The International Liver Con-
gress and Digestive Diseases Week (DDW). If conference
abstracts are not adequately comprehensive, we will use
the information from these abstracts to search for the
full text articles. We will attempt to contact the authors
of the conference abstracts if we are unable to track
down the full text articles. If we are unable to obtain the
full text articles and contact the authors, we will list the
studies as potentially relevant.
Manual searches
We will obtain reference lists of relevant studies identi-
fied, and the full text articles reviewed for inclusion in
the review will be checked for additional information.
Searching other sources
Grey Literature will include Google Scholar, SCOPUS for
conference proceedings. www.opengrey.eu and www.grey
lit.org. For ongoing studies, we will search the Pan African
National Clinical Trials Registry (PACTR), World Health
Organisation (WHO) International Clinical Trials Regis-
try Platform (ICTRP), and ClinicalTrials.gov and NHS
Clinical Trials. Individuals and organisations working in
the field of drug-induced liver injury will be consulted for
information regarding unpublished data and work in
progress.
Data collection and analysis
The methods for data collection and analysis will be
based on the Cochrane Handbook of Systematic Reviews
for Interventions [33].
Selection of studies
Two review authors (MFC and NK) will independently
review all relevant material identified from the above
search. After reading the titles and abstracts of the iden-
tified articles, we will acquire the full text articles of all
citations deemed to meet the inclusion criteria. These
articles will be independently inspected to verify that
they meet the pre-specified inclusion criteria. We will
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ing study eligibility through discussion with a third au-
thor (KC). For all studies excluded by the assessors, we
will describe the reasons for exclusion.Data extraction and management
MFC and NK will use a standardised data extraction
form to extract data from the included studies and to as-
sess the study quality. Extracted information will include
administrative details, verification assessment of the
diagnosis of DILI, details of the intervention, details of
comparators, details of outcomes and information for
assessment of the risk of bias. A pilot data extraction
will be performed using the data extraction form, and
the form will be modified if required. Any discrepancies
will be resolved via discussion of the original articles
with a third author (KC). We will request missing data
from study authors. References will be managed using
Mendeley Desktop reference manager and data will be
analysed using Review Manager 5.3 (RevMan5) software.
MFC and NK will both enter data and conduct cross-
checks to ensure that there are no data entry errors.Assessment of risk of bias in included studies
MFC and NK will independently assess the risk of bias
in each of the included studies. The assessment will in-
clude information on the following: sequence generation,
allocation concealment, blinding, incomplete outcome
data or missing data, selective outcome reporting, other
sources of bias and overall risk of bias. Each methodo-
logical component will be assessed, and the RCTs will be
described as having a low, unclear or high risk of bias,
as per the Cochrane Handbook of Systematic Reviews of
Interventions [33]. The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomized studies in
meta-analyses tool will be used for assessing the risk of
bias of the included cohort studies [34]. More specific-
ally, we will use an adapted version of the modified
NOS (see Additional file 2) to assess the risk of bias of
the included cohort studies [35]. This modified NOS in-
cludes seven questions amongst four domains of risk
assessment: methods for selecting study participants (se-
lection bias), methods to control for confounding (per-
formance bias), statistical methods (detection bias) and
methods of exposure and outcome assessment (informa-
tion bias). Risk of bias will be measured using a scale
ranging from 0 (high risk of bias) to 3 (low risk of bias),
and question-specific descriptions including examples of
varying degrees of bias are included. Items from the ori-
ginal NOS pertaining to adequacy of follow-up, selection
of participants (representativeness of cohort) and assess-
ment of outcomes will be retained in the adapted modi-
fied NOS.The two authors will resolve disagreements in the as-
sessment of risk of bias by discussion and consensus,
consulting KC to resolve any persistent disagreements.
Measures of treatment effect
Data will be analysed using RevMan5. The type of out-
comes may include dichotomous, continuous and time-
to-event data. For dichotomous data, a summary statistic
will be calculated (e.g. odds ratio and risk ratio) with
accompanying confidence interval (e.g. 95 % CI). For
continuous data, a summary statistic such as a mean dif-
ference or standardised mean difference will be calculated.
Two methods of summarising the time-to-event data will
be considered. The first will use the methods of survival
analysis and express the intervention effect as a hazard ra-
tio. For the second method, the time-to-event data may be
analysed as dichotomous data if the status of all study par-
ticipants at a fixed time point are known and further sum-
marised as an odds ratio or risk ratio with accompanying
confidence interval. Every effort will be made to contact
the original authors or investigators of the selected articles
to assist with missing or incomplete data.
Dealing with missing data
In the cases of absent or incomplete evidence found in
the included studies, authors will be contacted for fur-
ther information. We will report unclear issues as pre-
sented rather than make assumptions. Should they be
necessary, we will be explicit about assumptions made.
Data synthesis, assessment/investigation of heterogeneity
Heterogeneity will be assessed by inspecting forest plots
initially then through the Cochran’s chi-square test using
a 10 % level of significance cut-off (due to the low power
of the test) and the I-square statistic (I2) where values
will be evaluated as follows:
0–40 % =might not be important
30–60 % =moderate
50–90 % = substantial
75–100 % = considerable
Where heterogeneity is statistically significant, subgroup
analysis using the variables of age group, sex and setting
(e.g. geographical region), as well as sensitivity analysis,
will be conducted to explore the potential sources of het-
erogeneity. Symmetry of funnel plots will be used to assess
for publication or selective reporting bias.
We will attempt primary meta-analyses of the included
RCTs for both effectiveness and harm outcomes. If meta-
analysis of RCTs is feasible, a random effects model will be
constructed. We plan to quantify the statistical reliability
of data in the cumulative meta-analysis by undertaking se-
quential analysis. Should small study effects be found, we
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the identified RCTs are of substantial heterogeneity ren-
dering meta-analysis not feasible, the findings will be pre-
sented in narrative form and will include relevant tables
and figures to aid in data presentation. We will consider
conducting separate secondary meta-analyses for pro-
spective cohort studies limited to the outcomes of harm.
If this is not feasible, the findings from the included cohort
studies will be presented in a narrative form. All authors
will contribute to the narrative review.
In addition to evaluating all DILI participants, we also
plan to explore differences in outcomes between the fol-
lowing subgroups: sex, age strata, geographical region,
diagnostic certainty of DILI and exclusion of other pos-
sible causes, aetiology of DILI (e.g. antituberculous, HIV
antiretrovirals, antiepileptics, herbal supplements), coma
grade, severity of DILI (using severity scales such as
Drug-Induced Liver Injury Network 5-point scale where
severity of liver injury is based upon the presence of
jaundice, hospitalisation, signs of hepatic or other organ
failure, ultimate outcome and graded as 1+ mild, 2+
moderate, 3+ moderate-severe, 4+ severe, 5+ fatal) and
pattern of liver injury (hepatocellular, mixed and chole-
static). For the analyses of outcomes within subgroups,
the same methods of analyses for measuring treatment
effects as a whole will be applied.
We will use the grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
to assess the quality of evidence [36].
Sensitivity analyses
A sensitivity analysis of the findings from primary meta-
analysis is planned, and the aim is to determine whether
the findings are robust to decisions made during the re-
view process [32]. Amongst others, we will explore the
impact of including or excluding particular studies and
the chosen method for analysis. Lastly, we will also
evaluate the impact of excluding studies deemed as hav-
ing a high risk of bias.
Presenting and reporting of results
This systematic review will be reported according to the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) statement [37].
Discussion
This review will provide evidence on the effectiveness and
safety of NAC in non-paracetamol DILI. We anticipate
that the findings could aid health care practitioners and
policymakers in the decision-making regarding the use of
NAC in patients with non-paracetamol DILI. Further-
more, the findings may benefit researchers by providing
guidance for the focus of future research through the
identification of gaps in the existing evidence and adviseon the conduct of future high-quality research through
the identification of the shortcomings in previously con-
ducted research.
Additional files
Additional file 1: Electronic search strategy. This describes the
electronic search strategy used in searching the electronic databases.
Additional file 2: Modified Newcastle-Ottawa Scale. This describes an
adapted version of a modified Newcastle-Ottawa Scale for the risk of bias
assessment of included cohort studies.
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